Shigeki Nanjo

2.4k total citations
54 papers, 1.6k citations indexed

About

Shigeki Nanjo is a scholar working on Pulmonary and Respiratory Medicine, Oncology and Molecular Biology. According to data from OpenAlex, Shigeki Nanjo has authored 54 papers receiving a total of 1.6k indexed citations (citations by other indexed papers that have themselves been cited), including 37 papers in Pulmonary and Respiratory Medicine, 37 papers in Oncology and 18 papers in Molecular Biology. Recurrent topics in Shigeki Nanjo's work include Lung Cancer Treatments and Mutations (33 papers), Lung Cancer Research Studies (23 papers) and Cancer Genomics and Diagnostics (7 papers). Shigeki Nanjo is often cited by papers focused on Lung Cancer Treatments and Mutations (33 papers), Lung Cancer Research Studies (23 papers) and Cancer Genomics and Diagnostics (7 papers). Shigeki Nanjo collaborates with scholars based in Japan, United States and Italy. Shigeki Nanjo's co-authors include Seiji Yano, Shinji Takeuchi, Tadaaki Yamada, Takayuki Nakagawa, Nobuyuki Katakami, Hiromichi Ebi, Akito Hata, Daisuke Ishikawa, Kunio Matsumoto and Trever G. Bivona and has published in prestigious journals such as Science, Journal of Clinical Investigation and Journal of Clinical Oncology.

In The Last Decade

Shigeki Nanjo

51 papers receiving 1.6k citations

Peers

Shigeki Nanjo
Xian Lu United States
Yoshio Tomizawa Japan
Masaharu Nomura Japan
Jong-Yeon Shin South Korea
Ulrike Tontsch-Grunt Austria
Sergi Benavente Spain
Katsumi Koshikawa Japan
Kathryn E. Ware United States
Giorgia Migliardi Italy
S. Vignati Italy
Xian Lu United States
Shigeki Nanjo
Citations per year, relative to Shigeki Nanjo Shigeki Nanjo (= 1×) peers Xian Lu

Countries citing papers authored by Shigeki Nanjo

Since Specialization
Citations

This map shows the geographic impact of Shigeki Nanjo's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Shigeki Nanjo with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Shigeki Nanjo more than expected).

Fields of papers citing papers by Shigeki Nanjo

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Shigeki Nanjo. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Shigeki Nanjo. The network helps show where Shigeki Nanjo may publish in the future.

Co-authorship network of co-authors of Shigeki Nanjo

This figure shows the co-authorship network connecting the top 25 collaborators of Shigeki Nanjo. A scholar is included among the top collaborators of Shigeki Nanjo based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Shigeki Nanjo. Shigeki Nanjo is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Koba, Hayato, Hideharu Kimura, Isao Matsumoto, et al.. (2025). Prognostic value of preoperative ctDNA and pathological venous invasion for recurrence in EGFR-mutated non-small cell lung cancer. Lung Cancer. 213. 108818–108818.
2.
3.
Koba, Hayato, Shigeki Nanjo, & Seiji Yano. (2024). Abstract 5194: Pre-operative markers extracted from extracellular vesicles related with lung cancer relapse. Cancer Research. 84(6_Supplement). 5194–5194. 1 indexed citations
4.
Quinn, Jeffrey J., Matthew G. Jones, Ross A. Okimoto, et al.. (2021). Single-cell lineages reveal the rates, routes, and drivers of metastasis in cancer xenografts. Science. 371(6532). 183 indexed citations
5.
Arai, Sachiko, Shinji Takeuchi, Koji Fukuda, et al.. (2020). Osimertinib Overcomes Alectinib Resistance Caused by Amphiregulin in a Leptomeningeal Carcinomatosis Model of ALK-Rearranged Lung Cancer. Journal of Thoracic Oncology. 15(5). 752–765. 22 indexed citations
6.
Fukuda, Koji, Shinji Takeuchi, Sachiko Arai, et al.. (2019). Epithelial-to-Mesenchymal Transition Is a Mechanism of ALK Inhibitor Resistance in Lung Cancer Independent of ALK Mutation Status. Cancer Research. 79(7). 1658–1670. 79 indexed citations
7.
8.
Nanjo, Shigeki, Sachiko Arai, Wei Wang, et al.. (2017). MET Copy Number Gain Is Associated with Gefitinib Resistance in Leptomeningeal Carcinomatosis of EGFR -mutant Lung Cancer. Molecular Cancer Therapeutics. 16(3). 506–515. 47 indexed citations
9.
Hata, Akito, Nobuyuki Katakami, Shigeki Nanjo, et al.. (2017). Rebiopsy of Histological Samples in Pretreated Non-small Cell Lung Cancer: Comparison Among Rebiopsy Procedures. In Vivo. 31(3). 475–479. 7 indexed citations
10.
Nanjo, Shigeki, Akito Hata, Chiyuki Okuda, et al.. (2017). Standard-dose osimertinib for refractory leptomeningeal metastases in T790M-positive EGFR-mutant non-small cell lung cancer. British Journal of Cancer. 118(1). 32–37. 69 indexed citations
11.
Hata, Akito, Nobuyuki Katakami, Shigeki Nanjo, et al.. (2017). Programmed death-ligand 1 expression and T790M status in EGFR -mutant non-small cell lung cancer. Lung Cancer. 111. 182–189. 33 indexed citations
12.
Tanimoto, Azusa, Shinji Takeuchi, Hiroshi Yaegashi, et al.. (2016). Recurrence of renal cell carcinoma diagnosed using contralateral adrenal biopsy with endoscopic ultrasound-guided fine-needle aspiration. Molecular and Clinical Oncology. 4(4). 537–540. 1 indexed citations
13.
Kotani, Hiroshi, Hiromichi Ebi, Hidenori Kitai, et al.. (2015). Co-active receptor tyrosine kinases mitigate the effect of FGFR inhibitors in FGFR1-amplified lung cancers with low FGFR1 protein expression. Oncogene. 35(27). 3587–3597. 32 indexed citations
14.
Nanjo, Shigeki, Takayuki Nakagawa, Shinji Takeuchi, et al.. (2015). In vivo imaging models of bone and brain metastases and pleural carcinomatosis with a novel human EML4‐ALK lung cancer cell line. Cancer Science. 106(3). 244–252. 30 indexed citations
15.
Nakagawa, Takayuki, Shinji Takeuchi, Tadaaki Yamada, et al.. (2013). EGFR-TKI Resistance Due to BIM Polymorphism Can Be Circumvented in Combination with HDAC Inhibition. Cancer Research. 73(8). 2428–2434. 136 indexed citations
16.
Nakagawa, Takayuki, Shinji Takeuchi, Tadaaki Yamada, et al.. (2012). Combined Therapy with Mutant-Selective EGFR Inhibitor and Met Kinase Inhibitor for Overcoming Erlotinib Resistance in EGFR -Mutant Lung Cancer. Molecular Cancer Therapeutics. 11(10). 2149–2157. 74 indexed citations
17.
Yamada, Tadaaki, Shinji Takeuchi, Junya Nakade, et al.. (2012). Paracrine Receptor Activation by Microenvironment Triggers Bypass Survival Signals and ALK Inhibitor Resistance in EML4-ALK Lung Cancer Cells. Clinical Cancer Research. 18(13). 3592–3602. 93 indexed citations
18.
Hata, Akito, Nobuyuki Katakami, Hiroshige Yoshioka, et al.. (2011). Erlotinib after gefitinib failure in relapsed non-small cell lung cancer: Clinical benefit with optimal patient selection. Lung Cancer. 74(2). 268–273. 53 indexed citations
19.
Tachikawa, Ryo, Keisuke Tomii, Hiroyuki Ueda, et al.. (2011). Clinical Features and Outcome of Acute Exacerbation of Interstitial Pneumonia: Collagen Vascular Diseases-Related versus Idiopathic. Respiration. 83(1). 20–27. 101 indexed citations
20.
Hata, Akito, Nobuyuki Katakami, Shiro Fujita, et al.. (2010). Amrubicin at a lower-dose with routine prophylactic use of granulocyte-colony stimulating factor for relapsed small-cell lung cancer. Lung Cancer. 72(2). 224–228. 5 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Xian Lu Breakdown of academic impact, for papers by Yoshio Tomizawa Breakdown of academic impact, for papers by Masaharu Nomura Breakdown of academic impact, for papers by Jong-Yeon Shin Breakdown of academic impact, for papers by Ulrike Tontsch-Grunt Breakdown of academic impact, for papers by Sergi Benavente Breakdown of academic impact, for papers by Katsumi Koshikawa Breakdown of academic impact, for papers by Kathryn E. Ware Breakdown of academic impact, for papers by Giorgia Migliardi Breakdown of academic impact, for papers by S. Vignati
Rankless by CCL
2026